TipRanks on MSN

ADC Therapeutics Updates Strategic Focus on ZYNLONTA

ADC Therapeutics ( ($ADCT) ) just unveiled an announcement. On September 30, 2025, ADC Therapeutics released an updated corporate presentation ...
Morningstar

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio ...

Late-breaking data from IDeate-Lung01 phase 2 trial demonstrate potential of ifinatamab deruxtecan to become first-in-class B7-H3 directed ADC for pretreated extensive-stage small cell lung cancer ...
ksn.com

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ...

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 ...